Share ownership Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
369.19 ^USD	+1.52%		-3.94%	+12.80%

02-12	Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM
02-12	European Commission approves Amgen's Uplizna® for generalized myasthenia gravis	RE

Share class: Amgen Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	537,000,000	536,198,942 ( 99.85 %)	0	99.85 %

Major shareholders: Amgen Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 10.18 %	54,838,826	10.18 %	18 748 M $
BlackRock Advisors LLC 6.519 %	35,102,338	6.519 %	12 001 M $
STATE STREET CORPORATION 5.442 %	29,304,093	5.442 %	10 018 M $
Capital Research & Management Co. (World Investors) 4.289 %	23,097,711	4.289 %	7 897 M $
Capital Research & Management Co. (International Investors) 3.377 %	18,186,270	3.377 %	6 218 M $
Eaton Vance Management 2.955 %	15,910,524	2.955 %	5 439 M $
Geode Capital Management LLC 2.656 %	14,303,294	2.656 %	4 890 M $
Ishares (DE) InvAG mit Teilgesellschaftsvermogen 2.053 %	11,054,197	2.053 %	3 779 M $
PRIMECAP Management Co. 1.654 %	8,904,979	1.654 %	3 044 M $
Wells Fargo Bank NA 1.527 %	8,221,191	1.527 %	2 811 M $
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Safra Asset CTVM SA (Investment Management) 0.000215 %	32,500	0.000215 %	397 718 $

Breakdown by shareholder type

Institutional	63.1%
Other	8.13%
State Street Corp.	5.44%
Sumitomo Mitsui Trust Group, Inc.	0.3%
Schweizerische Nationalbank	0.27%
Manulife Financial Corp.	0.17%
Individuals	0.17%
Governments	0.13%
SEI Investments Co.	0.1%
Swedbank AB	0.08%
Danske Bank A/S	0.05%
Fifth Third Bancorp	0.05%
First Financial Bankshares, Inc.	0.04%
The Bank of Nova Scotia	0.03%
Skandinaviska Enskilda Banken AB	0.03%
Hancock Whitney Corp.	0.03%
Commerzbank AG	0.03%
Silvercrest Asset Management Group, Inc.	0.02%
Banco Bilbao Vizcaya Argentaria SA	0.02%
Peapack-Gladstone Financial Corp.	0.02%
Zurich Insurance Group AG	0.02%
Sumitomo Mitsui Financial Group, Inc.	0.01%
Cullen/Frost Bankers, Inc.	0.01%
First Horizon Corp. (Tennessee)	0.01%
Tompkins Financial Corp.	0.01%
The Allstate Corp.	0.01%
Kinsale Capital Group, Inc.	0.01%
Hilltop Holdings, Inc.	0.01%
Ledyard Financial Group, Inc.	0.01%
Unknown	21.68%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	60.98%
United Kingdom	4.8%
Canada	2.4%
Germany	2.36%
Norway	1.38%
Japan	0.9%
France	0.72%
Australia	0.72%
Switzerland	0.67%
Sweden	0.67%
Denmark	0.65%
South Korea	0.29%
Netherlands	0.29%
Hong Kong	0.28%
Luxembourg	0.21%
Individuals	0.17%
Belgium	0.17%
Ireland	0.16%
Italy	0.12%
China	0.11%
Finland	0.07%
Austria	0.06%
Czech Republic	0.03%
New Zealand	0.03%
Spain	0.03%
Singapore	0.01%
India	0.01%
Brazil	0.01%
South Africa	0.01%
Poland	0.01%

Based on 1000 largest holdings

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.4% of net sales.

Employees

28,000

Sector

Pharmaceuticals

Calendar

04-28 - Q1 2026 Earnings Release (Projected)

More about the company